Skip to main content

Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS), Alkermes (ALKS) and Summit Therapeutics (SMMT)

Tipranks - Tipranks - Wed Feb 25, 2:44AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioLife Solutions (BLFS – Research Report), Alkermes (ALKS – Research Report) and Summit Therapeutics (SMMT – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

BioLife Solutions (BLFS)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on BioLife Solutions yesterday. The company’s shares closed last Monday at $22.88.

According to TipRanks.com, Hewitt ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.8% and a 36.3% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Park Dental Partners, Inc., and Dyadic International. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioLife Solutions with a $33.25 average price target, representing a 44.6% upside. In a report issued on February 12, Lake Street also maintained a Buy rating on the stock with a $33.00 price target.

See the top stocks recommended by analysts >>

Alkermes (ALKS)

In a report released yesterday, Rudy Li from Wolfe Research initiated coverage with a Buy rating on Alkermes and a price target of $45.00. The company’s shares closed last Monday at $32.19.

According to TipRanks.com, Li is a 5-star analyst with an average return of 70.4% and a 54.0% success rate. Li covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Centessa Pharmaceuticals, and Definium Therapeutics. ;'>

Currently, the analyst consensus on Alkermes is a Strong Buy with an average price target of $44.44, implying a 40.5% upside from current levels. In a report issued on February 10, Jefferies also maintained a Buy rating on the stock with a $58.00 price target.

Summit Therapeutics (SMMT)

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Summit Therapeutics. The company’s shares closed last Monday at $16.09.

According to TipRanks.com, Buren is a 5-star analyst with an average return of 19.1% and a 54.1% success rate. Buren covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Crinetics Pharmaceuticals, and Bicara Therapeutics Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Summit Therapeutics with a $57.98 average price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).